Abstract: Melphalan flufenamide (melflufen) is a first-in-class peptide?drug conjugate that takes advantage of increased aminopeptidase activity inside tumor cells to rapidly release alkylating agents therein. Melflufen in combination with dexamethasone has been evaluated in multiple clinical trials in patients with relapsed/refractory multiple myeloma (MM).

Authorship

Download reference